Durect's ROE % for the quarter that ended in Dec. 2023 was -39.49%. Durect's PB Ratio for the quarter that ended in Dec. 2023 was 1.21.
Durect's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2023 was -32.64%.
Durect ROE % Adjusted to Book Value Historical Data
The historical data trend for Durect's ROE % Adjusted to Book Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Durect's ROE % Adjusted to Book Value
For the Drug Manufacturers - Specialty & Generic subindustry, Durect's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Durect's ROE % Adjusted to Book Value Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Durect's ROE % Adjusted to Book Value distribution charts can be found below:
* The bar in red indicates where Durect's ROE % Adjusted to Book Value falls into.
Durect ROE % Adjusted to Book Value Calculation
Durect's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Durect ROE % Adjusted to Book Value Related Terms
Thank you for viewing the detailed overview of Durect's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Durect Corp is a biopharmaceutical company. It is engaged in the research, development, and manufacturing of pharmaceutical products. The company develops pharmaceutical products based on two categories which include new chemical entities and proprietary pharmaceutical programs. The company's pipeline products consist of DUR-928, POSIMIR, and others. Geographically, the company operates in the United States, Europe, Japan, and other countries, of which key revenue is derived from the Europe .
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
DRRX has been successfully added to your 